Bone Marrow & Stem Cell Transplant

Samer A. Srour, MD, discusses Orca Q graft and how it’s revolutionized haploidentical allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed relapse after transplant for patients with cancer and what is important to note moving forward with research.

Robert J. Soiffer, MD, discusses the role of transplantation and relapse after transplant for patients with cancer.

An expert on graft-vs-host disease provides an overview of GVHD prophylaxis and conditioning regimens prior to transplant.

Yi-Bin Chen, MD, an expert clinician and researcher, reviews a case study of a patient with GVHD and offers his initial impressions.

In an interview with Targeted Oncology, Lori Muffly, MD, discusses the subanalysis of a phase 1 study of briquilimab plus low-dose total body radiation and fludarabine which was presented at 2023 Tandem Meetings on Transplantation and Cellular Therapy.

In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the full data from the phase 2 trial of panobinostat, gemcitabine, busulfan, and melphalan for patients with high-risk, relapsed/refractory myeloma.

Samer A. Srour, MD, MS, discusses some of the takeaways from the dose-expansion phase of an ongoing phase 1 trial evaluating Orca-Q.

The phase 3 GRAPHITE study showed that vedolizumab plus standard prophylaxis after unrelated allogeneic hematopoietic stem cell transplantation was more effective vs placebo for the prevention of lower gastrointestinal graft-vs-host disease.

In findings from the phase 3 SIERRA trial, Iomab-B-based conditioning for patients with relapsed or refractory acute myeloid leukemia provided significant efficacy and tolerable safety results over the current standard of care.

Tisagenlecleucel reinfusion shows promise as as an effective bridge to hematopoietic stem cell transplantation in pediatric B-cell acute lymphoblastic leukemia.

Novel treatments are needed to replace transplant and prevent graft-vs-host disease in order to improve patient outcomes.

Long-term outcomes did not differ among de novo late acute graft-vs-host disease and classic acute graft-vs-host disease, showing they should be treated the same way.

Yago Nieto, MD, PhD, discusses the findings from a phase 2 trial evaluating treatment with panobinostat, gemcitabine, busulfan, and melphalan for high-risk or relapsed/refractory myeloma.

Regardless of prior therapies, brexucabtagene autoleucel showed a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, according to subgroup analyses of the phase 3 ZUMA-3 trial.

Risk of relapse was significantly greater for those with acute lymphoblastic leukemia who had low minimal residual disease of less than 10-4 vs those with undetectable MRD, according to results of a retrospective study.

The first-in-human phase 1 trial of ADI-001 as a treatment for patients with relapsed/refractory B-cell non-Hodgkin lymphoma led to responses and a favorable safety profile.

Data comparing 4 donor types showed matched sibling donors to be preferred in patients with myelofibrosis, according to a presentation given at the 2023 Transplantation and Cellular Therapy Meeting.

Melhem Solh, MD, discusses the future for patients with myelodysplastic syndrome and acute myeloid leukemia that harbors a TP53 gene mutation, and gives his own recommendations to community oncologists who are treating patients with this disease.

Based on findings from the phase 2 CARDAMON studies, further research is needed to explore deferred autologous hematopoietic stem-cell transplantation in some subgroups of patients with multiple myeloma.

In an interview with Targeted Oncology, Guenther Koehne, MD, PhD provided a detailed explanation on the impact of cytomegalovirus reactivation post-transplant, cytomegalovirus reactivation prevention, and refractory cytomegalovirus reactivation.

Robert J. Soiffer, MD, discusses the role of transplant in the post chimeric antigen receptor setting for patients with hematologic malignancies.

While upfront transplant showed benefit vs carfilzomib, cyclophosphamide, and dexamethasone in the phase 2 CARDAMON study of patients with multiple myeloma, 57.7% of patients achieved at least a very good partial response with the combination.

Melhem M. Solh, MD, discusses results of a study investigating allogeneic stem cell transplant in patients with myelodysplastic syndrome and acute myeloid leukemia with a TP53 mutation, previously presented at the 2022 Transplantation & Cellular Therapy Meetings.

Favorable long-term survival rates and manageable rates of graft-vs-host disease were elicited with omidubicel in patients with hematologic malignancies who underwent allogeneic stem cell transplant.

Robert J. Soiffer, MD, discusses the use of transplant in various hematologic malignancies.

Randomized studies examining patients with peripheral T-cell lymphoma regarding the role of transplant are lacking and more research is needed to personalize therapy for patients based on subtype, biomarkers, mutational profiling, and radiographic parameters.

More interventions are needed to address fatigue in survivors of cancer and hematopoietic stem cell transplant.

Salman Fazal, MD, explains how to lower the risk of graft-versus-host disease in patients who undergo allogeneic stem cell transplant.